Cell biology

Yemaachi Presents Findings on Mutation Profiles of Ghanaian Women with Breast Cancer at AORTIC 2023; Announces Formation of African Clinical Cancer Research Network

Retrieved on: 
Monday, November 6, 2023
Research, Professional Services, Data Management, Oncology, Consumer, Technology, Genetics, Health Technology, Data Analytics, Science, Biotechnology, Women, Health, VAF, System, Therapy, TP53, BRCA1, PIK3CA, Conference, NF1, University, BRCA2, Sequence, Breast cancer, Hospital, Cell biology, Woman, Patient, Vision, African, Pharmaceutical industry, Cancer

The study profiled 106 samples of Ghanaian women with breast cancer with whole exome sequencing to identify associated somatic and driver mutations.

Key Points: 
  • The study profiled 106 samples of Ghanaian women with breast cancer with whole exome sequencing to identify associated somatic and driver mutations.
  • The network will be focused on promoting pan-African cancer research, led by African clinicians and scientists and performed on the continent.
  • Yemaachi already has an extensive network of 24 academic institutions, corporate partners, and hospitals across nine African countries who will be founding network members.
  • To learn more about participating in the AfriCAN network, potential members can get in touch at [email protected] .

Kite and Epic Bio Announce Collaboration to Develop New Therapies for Cancer

Retrieved on: 
Tuesday, October 31, 2023
Oncology, Health, Stem Cells, Hospitals, Genetics, Pharmaceutical, Biotechnology, Gene, Translational medicine, CAR, Cancer, EPS, GAAP, Patient, Bone marrow, Cell biology, Pharmaceutical industry

Kite, a Gilead Company (Nasdaq: GILD) and Epicrispr Biotechnologies (“Epic Bio”), today announced the companies have entered into a research collaboration and license agreement using Epic Bio’s proprietary gene regulation platform to develop next-generation cancer cell therapies.

Key Points: 
  • Kite, a Gilead Company (Nasdaq: GILD) and Epicrispr Biotechnologies (“Epic Bio”), today announced the companies have entered into a research collaboration and license agreement using Epic Bio’s proprietary gene regulation platform to develop next-generation cancer cell therapies.
  • “Cell-based cancer immunotherapies have reshaped modern cancer care, but we have still only scratched the surface of their potential benefit for patients.
  • Kite will make an upfront payment to Epic Bio and Epic Bio will be eligible to receive performance-based development, regulatory and sales milestone payments.
  • Epic Bio is also eligible to receive tiered royalties on any approved products that result from the collaboration.

Global Protein Labeling Market Size, Share & Trends Analysis Report 2023-2030 - Innovative Techniques Propel Global Protein Labeling Market Forward - ResearchAndMarkets.com

Retrieved on: 
Friday, October 27, 2023
Biotechnology, Science, Health, Research, Molecular biology, Biomarker, Copenhagen, Cell biology, Reagent, PTM, Investment, Cell, Mass spectrometry, Novo Nordisk Foundation Center for Protein Research, Medical research, University of Copenhagen Faculty of Health and Medical Sciences, Growth, Genomics, Immune system, A-DNA, Neuroscience, Biochemistry, University, USD, Mass, Novo Nordisk Foundation, Proteomics, Biomedicine, Assay, Medical imaging, Vaccine, Pharmaceutical industry

Protein labeling is undergoing a significant transformation, driven by the burgeoning interest in Post-translational Modification (PTM) studies.

Key Points: 
  • Protein labeling is undergoing a significant transformation, driven by the burgeoning interest in Post-translational Modification (PTM) studies.
  • The application of advanced quantification methods, such as iodoTMTzero Label Reagent, is facilitating the efficient detection of PTMs, propelling the market forward.
  • Biomedical research is at the forefront of driving growth in the global protein labeling market.
  • The surge in PTM studies, fueled by breakthroughs in protein expression quantification and innovative tagging strategies, is a pivotal factor.

Yulex, LLC Announces the Appointment of Former Biotech Executive as its New Chief Executive Officer

Retrieved on: 
Tuesday, October 31, 2023
Human, Piper, ABA, Diversity, Pepperdine University School of Law, DLA Piper, Family, Intellectual property, Research, Sibling, MLK, Persepolis Athletic and Cultural Club, Decathlon, Growth, Marketing, Partnership, SE, Cell biology, University, Vertex Pharmaceuticals, UCLA, Entrepreneurship, Tulane University, Parent, Management, Yulex, Southeast Asia

LAS VEGAS, Oct. 31, 2023 /PRNewswire/ -- Yulex, LLC, today announces the promotion of Dr. Elizabeth (Liz) Bui to Chief Executive Officer.

Key Points: 
  • LAS VEGAS, Oct. 31, 2023 /PRNewswire/ -- Yulex, LLC, today announces the promotion of Dr. Elizabeth (Liz) Bui to Chief Executive Officer.
  • Liz is an accomplished executive with more than two decades of leadership experience in diverse functional areas including corporate development, intellectual property and licensing, research & development, marketing, and diversity & inclusion.
  • Dr. Bui joined Yulex in January 2022 as Chief Business Officer as part of its succession planning program.
  • In addition, Liz was the chief architect behind the recently announced partnership with Decathlon, the world's largest retail sporting goods company.

Microcarrier Market Poised to Reach $3.43 Billion by 2030: Driving Advances in Biopharmaceuticals and Vaccine Production - ResearchAndMarkets.com

Retrieved on: 
Thursday, October 19, 2023
Biotechnology, Pharmaceutical, Health, Media, Research, Regenerative medicine, Incidence, Microcarrier, Vaccine, Cell biology, Reagent, Research and development, Conditional sentence, Diabetes, Bioreactor, Rheumatoid arthritis, Tissue engineering, Cell, Downstream processing, Institute of Information Technology Advancement, Environment, Lead, Cancer, Consumables, Pharmaceutical industry, Veterinary medicine, Fine chemical, Growth

The global Microcarrier Market is poised to achieve a substantial valuation of US$ 3.43 billion by 2030, according to a comprehensive market analysis.

Key Points: 
  • The global Microcarrier Market is poised to achieve a substantial valuation of US$ 3.43 billion by 2030, according to a comprehensive market analysis.
  • The Microcarrier Market is experiencing significant growth, driven by the need to enhance vaccine production yields, reduce costs, and address a wide range of diseases.
  • These beads provide a flexible platform for cell attachment and growth, facilitating the production of biopharmaceuticals, vaccines, and cell-based therapies.
  • The United States stands out in the Microcarrier Market, known for its innovation and technological advancements.

Semarion Announces Early Adopter Programme for SemaCyte Microcarrier Platform

Retrieved on: 
Wednesday, October 18, 2023
Science, Stem Cells, Biotechnology, Research, Pharmaceutical, Health, Medical Devices, Health Technology, Laboratory, Cavendish Laboratory, Material, Patent, Cell biology, Cell, Nanomagnet, Engineering, Growth, University of Cambridge, Drug discovery, Freezing, University, Early adopter, Fine chemical, Pharmaceutical industry

Semarion Ltd, a University of Cambridge spin-out company from the Cavendish Laboratory combining materials engineering and cell biology to tackle unmet drug screening needs, today announced the opening of its Early Adopter Programme for its SemaCyte® Microcarrier Platform.

Key Points: 
  • Semarion Ltd, a University of Cambridge spin-out company from the Cavendish Laboratory combining materials engineering and cell biology to tackle unmet drug screening needs, today announced the opening of its Early Adopter Programme for its SemaCyte® Microcarrier Platform.
  • Researchers are now invited to register their interest to be included in the Company’s Early Adopter Programme, which will allow access to the SemaCyte Microcarrier Platform and provide first-hand experience of how the technology can improve drug discovery workflows.
  • Jeroen Verheyen, Co-Founder & CEO, Semarion, said: “We are delighted to open the Early Adopter Programme for our SemaCyte Microcarrier Platform to researchers working in drug discovery.
  • The SemaCyte Microcarrier Platform is uniquely positioned to address a significant market opportunity and revolutionise in vitro drug discovery by innovating adherent cell assays to produce better data, faster.”
    For more information about Semarion’s SemaCyte Microcarrier Platform, please visit: www.semarion.com/semacyte/ .

Eighteenth edition of Fujio Cup Quiz won by Kasturba Medical College, India in the NCRM NICHE 2023 international stem cell meeting.

Retrieved on: 
Wednesday, October 18, 2023
Research, Hospitals, Health Technology, Stem Cells, Biotechnology, Training, University, Health, Science, Education, Cellular senescence, Regenerative medicine, PD, Cell biology, Urethral stricture, IDC, Tissue engineering, FCQ, Sri Ramachandra Institute of Higher Education and Research, Cell, GSZ, Multimedia, Tree (graph theory), Code, Tissue, German Society for Stem Cell Research, Genome, Kasturba Medical College, Disease, Buccal, University of Cologne, Duchenne muscular dystrophy, XVIII, Radboud University Medical Center, Hospital, Chondrocyte, McEwen Centre for Regenerative Medicine, Stem cell, Multiple sclerosis, NCRM, Thai-Nichi Institute of Technology, Safety, DMD, Autism spectrum, Synthetic biology, ASD, Edogawa, MS, B cell, Pharmaceutical industry, RM

This press release features multimedia.

Key Points: 
  • This press release features multimedia.
  • Winners and finalists of Fujio Cup Quiz (FCQ), the “FCQ Elites” are qualified to nominate the candidates for the Edogawa NICHE Prize.
  • The inaugural prize in 2018 was awarded to Prof. James E. Till for discovery of stem cells, jointly with Prof. Ernest McCulloch.
  • NCRM NICHE team is progressing in research on implications of microgravity, synthetic chemical concoctions, and biological response modifiers, on cellular senescence and immune modulation to develop solutions, especially for rare diseases and unmet needs.

Why do some men not produce sperm? Stowers scientists collaborate to uncover one underlying reason for male infertility

Retrieved on: 
Friday, October 20, 2023
Dai, Meiosis, Gene editing, Sainsbury Wellcome Centre for Neural Circuits and Behaviour, Medical research, Stowers Institute for Medical Research, Mouse, United States Army Simulation and Training Technology Center, Life, Human, Vertebrate, University, Research, Protein, Male, Science Advances, Egg, Cell biology, Animal, Synaptonemal complex, Disease, Research fellow, Infertility, Chromosome, Birth control, Vaccine, Science

KANSAS CITY, Mo., Oct. 20, 2023 /PRNewswire/ -- Millions of couples worldwide experience infertility with half of the cases originating in men.

Key Points: 
  • KANSAS CITY, Mo., Oct. 20, 2023 /PRNewswire/ -- Millions of couples worldwide experience infertility with half of the cases originating in men.
  • In most sexually reproducing species, including humans, a critical protein structure resembling a lattice-like bridge needs to be built properly to produce sperm and egg cells.
  • Previous studies have examined many proteins comprising the synaptonemal complex, how they interact with each other, and have identified various mutations linked to male infertility.
  • Just a single mutation, predicted from the modeling experiments, was verified as the culprit of infertility in mice.

Vilya Appoints Cyrus Harmon, Ph.D., as Chief Executive Officer

Retrieved on: 
Tuesday, October 17, 2023
Health, Technology, Health Technology, Nanotechnology, Artificial Intelligence, Biotechnology, Vitae, Cyrus, IPD, Scripps Research, Drug development, Machine learning, Bristol Myers Squibb, Berkeley, Coronavirus Scientific Advisory Board, University, Artificial intelligence, Therapy, Affymetrix, Protein, Molecular biology, Cell biology, Drug discovery, ARCH Venture Partners, Harmon, Pharmaceutical industry, Vilya, Muller's morphs

VILYA, Inc. (Vilya), a biotechnology company creating a new class of medicines that precisely target disease biology, today announced the appointment of Cyrus Harmon, Ph.D., as its Chief Executive Officer.

Key Points: 
  • VILYA, Inc. (Vilya), a biotechnology company creating a new class of medicines that precisely target disease biology, today announced the appointment of Cyrus Harmon, Ph.D., as its Chief Executive Officer.
  • “I am very excited to join the phenomenal team at Vilya developing new macrocycle drugs,” said Harmon.
  • Previously, Harmon co-founded and served as CEO of Olema Oncology, a company focused on women’s cancers, before transitioning to the role of Chief Research Officer.
  • Harmon joins Katerina Leftheris, Ph.D., Vilya’s Chief Scientific Officer on the company’s leadership team.

Faeth Therapeutics Announces National Academy of Medicine Recognition for Co-founder Dr. Siddhartha Mukherjee

Retrieved on: 
Friday, October 13, 2023
Biotechnology, Pharmaceutical, Oncology, General Health, Health, Infectious Diseases, Hospitals, Other Health, National Academy of Medicine, Acute myeloid leukemia, Doctor of Philosophy, Memorial Sloan Kettering Cancer Center, Research, Francis Crick Institute, Bristol Myers Squibb, Harvard University, NAM, The Emperor of All Maladies, Cell biology, Medicine, National academy, Pulitzer Prize, Therapy, Immunotherapy, Genetics, Mukherjee, Assistant, Dana–Farber Cancer Institute, ARD International Music Competition, CRUK, Disease, Dana, National Academy of Science and Technology, Tony Faeth, Pharmaceutical industry

Faeth Therapeutics , a leader in metabolic oncology research and treatment innovation, proudly announces the induction of its co-founder, Dr. Siddhartha Mukherjee, Assistant Professor at Columbia, Pulitzer Prize Winner, and one of Time 100's Most Influential People, into the esteemed National Academy of Medicine (NAM).

Key Points: 
  • Faeth Therapeutics , a leader in metabolic oncology research and treatment innovation, proudly announces the induction of its co-founder, Dr. Siddhartha Mukherjee, Assistant Professor at Columbia, Pulitzer Prize Winner, and one of Time 100's Most Influential People, into the esteemed National Academy of Medicine (NAM).
  • "Dr. Mukherjee's induction into the National Academy of Medicine reaffirms Faeth Therapeutics' dedication to unparalleled scientific rigor and innovation.
  • In the National Academy of Medicine, members are elected by their colleagues as a testament to their exceptional accomplishments.
  • Being inducted into the academy represents one of the most prestigious accolades within the realm of medicine.